Orion Pharma Performance dei guadagni passati
Il passato criteri di controllo 1/6
Orion Pharma's earnings have been declining at an average annual rate of -6.1%, while the Pharmaceuticals industry saw earnings growing at 10.3% annually. Revenues have been growing at an average rate of 12.7% per year. Orion Pharma's return on equity is 1.9%, and it has net margins of 4%.
Informazioni chiave
-6.1%
Tasso di crescita degli utili
-6.1%
Tasso di crescita dell'EPS
| Pharmaceuticals Crescita del settore | 11.0% |
| Tasso di crescita dei ricavi | 12.7% |
| Rendimento del capitale proprio | 1.9% |
| Margine netto | 4.0% |
| Ultimo aggiornamento sui guadagni | 31 Mar 2024 |
Aggiornamenti sulle prestazioni recenti
Recent updates
Ripartizione dei ricavi e delle spese
Come Orion Pharma guadagna e spende denaro. In base agli ultimi utili dichiarati, su base LTM.
Storia dei guadagni e delle entrate
| Data | Ricavi | Guadagni | Spese G+A | Spese di R&S |
|---|---|---|---|---|
| 31 Mar 24 | 11,496 | 455 | 1,504 | 0 |
| 31 Dec 23 | 11,759 | 480 | 1,482 | 0 |
| 30 Sep 23 | 13,622 | 648 | 1,369 | 0 |
| 30 Jun 23 | 13,927 | 641 | 1,282 | 0 |
| 31 Mar 23 | 16,793 | 700 | 1,315 | 0 |
| 31 Dec 22 | 15,633 | 821 | 1,357 | 0 |
| 30 Sep 22 | 12,389 | 945 | 1,310 | 0 |
| 30 Jun 22 | 9,662 | 846 | 1,294 | 0 |
| 31 Mar 22 | 6,150 | 961 | 1,229 | 0 |
| 31 Dec 21 | 7,451 | 938 | 1,170 | 0 |
| 30 Sep 21 | 9,091 | 818 | 1,163 | 0 |
| 30 Jun 21 | 10,833 | 939 | 1,138 | 0 |
| 31 Mar 21 | 10,193 | 718 | 1,138 | 0 |
| 31 Dec 20 | 9,208 | 639 | 1,066 | 0 |
| 30 Sep 20 | 8,350 | 583 | 1,037 | 0 |
| 30 Jun 20 | 7,648 | 666 | 1,026 | 0 |
| 31 Mar 20 | 7,210 | 823 | 1,021 | 0 |
| 31 Dec 19 | 6,988 | 901 | 986 | 0 |
| 30 Sep 19 | 7,352 | 928 | 978 | 0 |
| 30 Jun 19 | 8,705 | 882 | 957 | 0 |
| 31 Mar 19 | 9,485 | 859 | 1,015 | 0 |
| 31 Dec 18 | 10,802 | 798 | 966 | 0 |
| 30 Sep 18 | 11,145 | 772 | 879 | 0 |
| 30 Jun 18 | 10,423 | 802 | 855 | 0 |
| 31 Mar 18 | 10,327 | 734 | 735 | 0 |
| 31 Dec 17 | 10,085 | 705 | 831 | 0 |
| 30 Sep 17 | 9,773 | 779 | 758 | 0 |
| 30 Jun 17 | 9,534 | 794 | 776 | 0 |
| 31 Mar 17 | 9,685 | 1,044 | 765 | 0 |
| 31 Dec 16 | 9,569 | 988 | 687 | 0 |
| 30 Sep 16 | 9,722 | 985 | 443 | 0 |
| 30 Jun 16 | 9,867 | 882 | 658 | 0 |
| 30 Sep 15 | 10,417 | 778 | 1,491 | 0 |
| 30 Jun 15 | 10,590 | 787 | 1,115 | 0 |
| 31 Mar 15 | 10,938 | 944 | 869 | 0 |
| 31 Dec 14 | 10,707 | 994 | 686 | 0 |
Guadagni di qualità: ORIONPHARM has high quality earnings.
Margine di profitto in crescita: ORIONPHARM's current net profit margins (4%) are lower than last year (4.2%).
Flusso di cassa libero e analisi degli utili
Analisi della crescita degli utili nel passato
Andamento degli utili: ORIONPHARM's earnings have declined by 6.1% per year over the past 5 years.
Accelerare la crescita: ORIONPHARM's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Guadagni vs Settore: ORIONPHARM had negative earnings growth (-34.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (-2.8%).
Rendimento del capitale proprio
ROE elevato: ORIONPHARM's Return on Equity (1.9%) is considered low.